Next Article in Journal
Lung Cancer Susceptibility and hOGG1 Ser326Cys Polymorphism: A Meta-Analysis
Next Article in Special Issue
Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and Epidemiology
Previous Article in Journal / Special Issue
CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2010, 2(4), 1794-1812; doi:10.3390/cancers2041794

Mucins and Pancreatic Cancer

INSERM, U837, Jean-Pierre Aubert Research Center, Team 5 "Mucins, epithelial differentiation and carcinogenesis", Lille, France
*
Author to whom correspondence should be addressed.
Received: 17 September 2010 / Revised: 14 October 2010 / Accepted: 18 October 2010 / Published: 25 October 2010
(This article belongs to the Special Issue Pancreatic Cancer)
View Full-Text   |   Download PDF [373 KB, 27 October 2010; original version 25 October 2010]   |  

Abstract

Pancreatic cancer is characterized by an often dramatic outcome (five year survival < 5%) related to a late diagnosis and a lack of efficient therapy. Therefore, clinicians desperately need new biomarkers and new therapeutic tools to develop new efficient therapies. Mucins belong to an ever increasing family of O-glycoproteins. Secreted mucins are the main component of mucus protecting the epithelia whereas membrane-bound mucins are thought to play important biological roles in cell-cell and cell-matrix interactions, in cell signaling and in modulating biological properties of cancer cells. In this review, we will focus on the altered expression pattern of mucins in pancreatic cancer, from the early neoplastic lesion Pancreatic Intraepithelial Neoplasia (PanIN) to invasive pancreatic carcinomas, and the molecular mechanisms (including genetic and epigenetic regulation) and signaling pathways known to control their expression. Moreover, we will discuss the recent advances about the biology of both secreted and membrane-bound mucins and their key roles in pancreatic carcinogenesis and resistance to therapy. Finally, we will discuss exciting opportunities that mucins offer as potential therapeutic targets in pancreatic cancer. View Full-Text
Keywords: pancreatic cancer; mucin; regulation; biomarker; therapy pancreatic cancer; mucin; regulation; biomarker; therapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Jonckheere, N.; Skrypek, N.; Van Seuningen, I. Mucins and Pancreatic Cancer. Cancers 2010, 2, 1794-1812.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top